Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
PRNewswire - October 23, 2000
(Photo:http://www.newscom.com/cgi-bin/prnh/20000119/VERTEXLOGO)
Agenerase will be available as soft capsules and as oral solution. Unlike most currently marketed PIs, Agenerase has a twice-daily dosing regimen without any food or water restrictions.
Agenerase is currently approved and marketed in Argentina, Brazil, Chile, Colombia, Ghana, Israel, Mexico, Switzerland, Uruguay, and the United States. Amprenavir is also approved in Japan where it is marketed by Vertex's partner Kissei Pharmaceutical Co., Ltd. under the trade name Prozei(TM).
Amprenavir was discovered by scientists at Vertex Pharmaceuticals of Cambridge, MA and licensed to Glaxo Wellcome in the United States, Europe, and other countries. Glaxo Wellcome has been responsible for product formulation and manufacture of Agenerase, design and implementation of clinical trials, and regulatory submissions. Glaxo Wellcome will market Agenerase in the European Union and Vertex will co-promote the drug in certain countries, where permitted by law.
Glaxo Wellcome is a research-based company whose people are committed to fighting disease by bringing innovative medicines and services to patients throughout the world and to healthcare providers who serve them.
Vertex Pharmaceuticals Incorporated discovers, develops and markets small molecule drugs that address major unmet medical needs. Vertex has 12 drug candidates in development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary, information-intensive approach to drug design that integrates multiple technologies in biology, chemistry and biophysics, aimed at increasing the speed and success rate of drug discovery. Vertex's first approved product is Agenerase(TM) (amprenavir), an HIV protease inhibitor, which Vertex co-promotes with Glaxo Wellcome.
This press release contains forward-looking statements about Vertex and Glaxo Wellcome's product, Agenerase, including statements about the use of Agenerase as a treatment option for patients who have failed previous PI therapy, and Glaxo Wellcome's ability to effectively market and sell Agenerase in the European Union. While management makes its best efforts to be accurate in making forward-looking statements, any such statements are subject to risks and uncertainties that could cause Vertex's actual results to vary materially.
Risk factors include uncertainties relating to Glaxo Wellcome's ability to effectively market and sell Agenerase in the European Union, Vertex's ability to protect its proprietary technologies, patent-infringement claims, and competitive technologies and drugs.
Agenerase is a trademark of the Glaxo Wellcome group of companies.
Vertex's press releases are available at http://www.vrtx.com, or by fax-on-demand at (800) 758-5804 - Code: 938395.
SOURCE Vertex Pharmaceuticals Incorporated Web Site: http://www.vpharm.com Photo Notes: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000119/VERTEXLOGO http://www.newscom.com/cgi-bin/prnh/20000502/BOGER AP Archive: http://photoarchive.ap.org PRN Photo Desk, 888-776-6555 or 201-369-3467
Company News On Call: http://www.prnewswire.com/comp/938395.html or fax, 800-758-5804, ext. 938395
001023
PR001035
Copyright © 2000 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .